Current Research Studies

Cancer – AALL1131: Phase 2 Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia including a Stratum Evaluating Dasatinib in Patients with Ph-like Tyrosine Kinase Inhibitor Sensitive Mutations

Condition or Therapy:

B acute lymphoblastic leukemia, CNS leukemia, Ph-like ALL, testicular leukemia


Cancer and blood disorders
Study Number: AALL1131

What is the goal of this study?

Researchers want to understand how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are 1 to 30 years old, and
  • Have been newly diagnosed with B lymphoblastic leukemia.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins